The strategy, termed Proactive Immune Training (PIT), draws its inspiration from an observation that has become increasingly clear over the course of the COVID-19 pandemic. People who experienced natural infection followed by vaccination—so-called hybrid immunity—tend to mount broader and more durable protection against reinfection and severe disease than those receiving either alone. The explanation lies in the evolutionary arms race that unfolds during a natural infection: as the virus mutates within the host, immune pressure selects for B cells capable of recognizing an expanding repertoire of antigenic shapes. This dynamic training drives somatic hypermutation and the eventual emergence of broadly neutralizing antibodies that can accommodate variant-level changes. The catch is obvious. Acquiring immunity through infection carries real risks of severe illness and death, and existing mRNA vaccines present only static antigens that cannot evolve inside the host, so they never recreate this dynamic antigenic landscape.

PIT was designed to reproduce that landscape synthetically, without the danger of infection. Using SARS-CoV-2 as a model, the research team, led by Xiangrong Song of Sichuan University, first turned to computational prediction. They applied the PyR0 pipeline, a hierarchical Bayesian regression framework trained on approximately 6.4 million SARS-CoV-2 genomes from GISAID, to estimate the fitness contribution of potential spike protein mutations. The model, which achieved an R-squared of 0.983 for fitness estimates in prior validation, ranks mutations by a Z-score that incorporates estimation uncertainty. From this global fitness landscape the researchers selected 30 high-probability mutation sites in the Spike protein, including well-characterized immune escape hotspots such as residues E484, K417, and N501, along with sites like L452, S477, N501, and P681 that have repeatedly defined variants of concern.

With the 30 sites in hand, the team performed saturation mutagenesis, systematically substituting every possible amino acid at each position to generate a DNA plasmid library of 600 distinct Spike antigens: 570 unique single-point mutants plus the wild-type sequence. Quality control was rigorous. Next-generation sequencing confirmed that residual wild-type had been reduced to 0.25 percent of the library, coverage of the intended mutants reached 98.4 percent, and a Gini coefficient of 0.17 indicated that the genetic diversity was evenly distributed rather than skewed toward a few dominant clones. Translational fidelity was verified by expressing ten representative mutants in HEK293T cells and quantifying Spike production by ELISA, which showed expression levels consistent with the wild-type protein. The plasmid pool was then transcribed in vitro into a matching mRNA library, ensuring that each training antigen retained its structural integrity while presenting deliberate variation at the key hotspots where immune escape is most likely to occur.

Delivering 600 different mRNA species simultaneously required an efficient and homogeneous delivery vehicle. The researchers formulated their library in lipid nanoparticles built around CMP1, an ionizable lipid developed in-house and protected under US Patent 11,839,657. Using microfluidic mixing, they produced particles averaging roughly 100 nanometers in diameter with a low polydispersity index of about 0.2. Nanoflow cytometry revealed an mRNA encapsulation efficiency of 90 percent and a remarkably low empty-particle ratio of 1.7 percent. In vitro, CMP1-based nanoparticles doubled the transfection efficiency achieved by the common reagent Lipofectamine 2000, and cryo-electron microscopy confirmed uniform, quasi-spherical particles with intact lipid bilayers. In mice, the platform showed preferential uptake by splenic dendritic cells and neutrophils, and confocal imaging demonstrated superior endosomal escape compared with the ALC-0315 lipid used in clinically approved mRNA vaccines, a critical property because mRNA trapped in lysosomes is degraded before it can be translated.

The immunization regimen itself was carefully staged. Mice first received a prime with a conventional single-antigen vaccine encoding the Delta variant Spike protein, establishing a foundational pool of memory B cells. Fourteen days later, a subset received a booster dose of the PIT vaccine containing the full 600-antigen m-library. The logic mirrors natural infection: the prime creates a high-quality substrate of memory, while the boost challenges that memory with a dense landscape of related but distinct variants, driving affinity maturation toward clones that can tolerate or recognize multiple mutational states. Control groups received two doses of the single-antigen vaccine, two doses of the PIT vaccine alone, or a hexavalent cocktail of six whole-Spike mRNAs spanning the wild-type, Alpha, Beta, Gamma, Delta, and Omicron BA.1 variants, providing a direct benchmark against a rational multivalent design.

The results of the prime-boost sequence were striking. The SA+PIT regimen elicited significantly higher serum IgG binding titers and pseudovirus neutralization titers across a panel of ten SARS-CoV-2 variants, including Alpha, Beta, Gamma, Delta, Omicron BA.2, BA.2.75, BA.5, and BF.7, compared with two doses of the single-antigen vaccine. Notably, BA.5 and BF.7 had not yet emerged when the PyR0 model was trained, so the breadth against these variants demonstrates genuine anticipatory capacity. When compared head-to-head with the hexavalent cocktail, the two strategies performed similarly against BA.2, which is antigenically close to the cocktail’s Omicron component, but the PIT-boosted group generated significantly higher binding and neutralizing titers against the more divergent BA.5 and BF.7 variants, with P values below 0.01. The authors interpret this as evidence that dense mutational coverage fills the antigenic gaps between discrete variants of concern, providing better protection against evolutionary drift within the predicted mutational space than a mixture of known strains.

Cellular immunity showed a parallel enhancement. Flow cytometry of splenocytes revealed that the SA+PIT regimen significantly increased the frequency of IFN-γ-producing CD4-positive and CD8-positive T cells, expanded the T follicular helper cell population that supports antibody maturation, and boosted IFN-γ production by B cells, while IL-2 responses remained comparable between vaccinated groups. Single-cell T cell receptor and B cell receptor sequencing, performed ten days after a rapid day-0/day-7 immunization schedule, showed markedly greater diversity in the BCR heavy chain and both kappa and lambda light chain repertoires, with a larger fraction of unique CDR3 sequences, the hypervariable regions that determine antigen specificity. The repertoires also displayed a transcriptomic shift toward the IgA subclass, hinting at broader isotype diversification, although mucosal IgA protein was not directly measured. Importantly, safety evaluations at a higher 50-microgram dose showed no significant changes in blood chemistry markers and no histopathological abnormalities in the heart, liver, spleen, lung, or kidney.

The authors are candid about the study’s limitations. The work remains a proof of concept based on surrogate endpoints such as ELISA binding and pseudovirus neutralization; no live-virus challenge experiments were performed, and protective efficacy must be confirmed in K18-hACE2 transgenic mice or non-human primates. Mechanistic cohorts were small, the BALB/c mouse model incompletely recapitulates human immunity, the study did not benchmark against clinically licensed mRNA vaccines such as BNT162b2 or mRNA-1273, and the manufacturing complexity of a 600-mutant library presents substantial hurdles for clinical-grade production. Germinal center dynamics, affinity maturation kinetics, and the precise epitopes underlying cross-reactivity also remain to be mapped. Yet the framework is inherently adaptable: the same combination of computational fitness prediction, saturation mutagenesis, and LNP delivery could, in principle, be extended to influenza or entirely novel pathogens, with artificial intelligence models predicting mutational landscapes directly from sequence data. The broader significance is conceptual. Vaccines have long been built to match the past; PIT suggests they could instead be built to anticipate the future, presenting the immune system with a cloud of evolutionary possibilities and letting it train against them before the virus ever gets the chance.

Subject of Research: A proactive mRNA vaccine strategy using a library of predicted SARS-CoV-2 Spike mutants to broaden antiviral immunity against future variants

Article Title: A proactive immune training strategy to generate anticipatory immunity against viral evasion

Article References: Qin, S., Teng, Y., Xin, J., Zhang, Y., Huang, L., Zhao, S., Jiao, X., Yin, X., Liu, S., Sun, J., Xu, W., Xie, Y., Liu, J., Kong, L., & Song, X. (2026). A proactive immune training strategy to generate anticipatory immunity against viral evasion. Journal of Advanced Research. https://doi.org/10.1016/j.jare.2026.08.059

Image Credits: AI Generated

DOI: 10.1016/j.jare.2026.08.059

Keywords: SARS-CoV-2, mRNA vaccine, Proactive Immune Training, viral immune evasion, broadly neutralizing antibodies, lipid nanoparticles, saturation mutagenesis, variant of concern, BCR repertoire, hybrid immunity, PyR0 model, vaccinology

A new study from Korea University College of Medicine, published in Nature Immunology on June 15, 2026, offers a detailed molecular portrait of how an mRNA-based influenza vaccine may accomplish exactly that. Led by Associate Professor Jiwon Lee of the Department of Convergence Medicine and the Vaccine Innovation Center, and conducted in collaboration with Professor Ali Ellebedy and his group at Washington University in St. Louis, the investigation compared an investigational quadrivalent mRNA influenza vaccine, designated mRNA-1010, against the licensed conventional split-virion vaccine Fluarix in a head-to-head clinical evaluation. The central question was whether the mRNA platform could stimulate stronger and more persistent germinal-center responses than a conventional vaccine, and whether that persistence would translate into a measurably broader antibody repertoire in the blood.

The germinal center is the crucible where vaccine-induced immunity is forged. Within specialized microenvironments of draining lymph nodes, B cells that recognize vaccine antigen undergo rounds of proliferation, somatic hypermutation, and selection. Each cycle introduces random mutations into the genes encoding the B-cell receptor, and only those variants whose mutated receptors bind antigen with higher affinity are permitted to survive and expand. Over weeks, this Darwinian process generates plasma cells that secrete high-affinity antibodies and memory B cells that persist for years. The duration and intensity of germinal-center activity are therefore widely regarded as key determinants of both the breadth and the durability of antibody responses. A vaccine that keeps germinal centers active for longer gives B cells more opportunities to mutate, diversify, and explore antibody solutions that recognize conserved or varied features of the virus.

To test whether mRNA vaccination extends this critical phase, the researchers enrolled 75 healthy adults aged 20 to 50 years and followed them across two influenza seasons. Of these, 38 participants received mRNA-1010 and 37 received Fluarix. Blood samples were collected at multiple time points through 26 weeks after vaccination, allowing the team to track the evolution of circulating antibodies over nearly half a year. Crucially, a subset of participants also underwent ultrasound-guided fine-needle aspiration of draining axillary lymph nodes, an invasive but informative procedure that enabled direct sampling of germinal centers as they formed and matured. This combination of peripheral blood monitoring and lymph-node sampling is rare in human vaccine studies and gave the investigators an unusually complete view of the immune response as it unfolded in real time.

The laboratory analysis was correspondingly comprehensive. The team deployed flow cytometry to characterize immune cell populations, ELISpot assays to quantify antigen-specific antibody-secreting cells, single-cell RNA sequencing and B-cell receptor sequencing to resolve individual B-cell lineages, serum IgG proteomics to catalog circulating antibody clonotypes, and a battery of antibody binding and neutralization assays to test functional activity against antigenically diverse influenza strains. Together, these methods profiled the response at scales ranging from single cells to whole serum, providing a multidimensional dataset that conventional vaccine trials, which typically rely on bulk antibody titers alone, cannot match.

The findings were striking. The mRNA vaccine elicited a substantially more diverse and broader serum antibody repertoire than Fluarix, according to Dr. Lee. Most notably, influenza-specific germinal-center responses persisted for up to 26 weeks in 5 of 13 mRNA-1010 recipients whose draining lymph nodes were sampled, while persistent germinal centers were not detected among any of the Fluarix recipients sampled. Six months of sustained germinal-center activity after a single vaccination is an unusually long window of B-cell evolution, and it suggests that the mRNA platform provides antigen persistence and inflammatory signaling that keep the selection machinery running far longer than a conventional protein-based split-virion preparation.

That prolonged activity left a measurable imprint on the antibody repertoire. The mRNA vaccine increased the diversity of the serum IgG repertoire and promoted the diversification of pre-existing B-cell lineages through somatic hypermutation, meaning that antibodies the immune system had already learned to make against earlier influenza exposures were not merely recalled but actively refined and expanded. These molecular changes were associated with broader antibody binding across antigenically diverse influenza strains and with significantly greater increases in neutralization titers against 11 of 13 A/H1N1 viruses tested. In practical terms, the antibodies generated after mRNA vaccination recognized a wider range of viral variants and neutralized more of them, including strains that differed antigenically from those contained in the vaccine itself. Dr. Lee summarized the distinction succinctly: the mRNA platform does not simply produce more antibodies, it produces a more diversified antibody response, which leads to greater binding and neutralizing breadth.

A key methodological strength of the study was Ig-Seq, a mass-spectrometry-based technology that identifies individual antibody clonotypes circulating in the blood after vaccination. Conventional vaccine studies typically measure bulk binding or neutralization titers, aggregate numbers that reveal how much antibody activity is present but say little about its composition. Ig-Seq resolves the response down to individual antibody clonotypes, revealing which antibody lineages emerged, expanded, and diversified after vaccination. Combined with B-cell receptor sequencing, this molecular-level approach allowed the researchers to trace the genealogical trees of antibody families as they mutated and branched over the six-month observation period, directly linking sustained germinal-center activity in the lymph node to the diversification of antibodies measurable in the serum. The authors identify Ig-Seq as a defining strength of the work because it captures information that bulk serology fundamentally cannot.

The broader implications reach toward the long-sought goal of a more universal influenza vaccine. If mRNA vaccination can sustain germinal-center activity for months rather than weeks, it creates a temporal window in which B cells can accumulate mutations that broaden their recognition of the virus’s antigenic landscape. This mechanism could in principle support protection that carries over between seasons, reducing the need for annual reformulation and re-vaccination. However, the authors are careful to note that further studies are needed to determine whether these broadened responses translate into multi-season protection or permit longer vaccination intervals. The study population consisted of healthy adults aged 20 to 50, and future research must investigate whether the same benefits are maintained in older adults and immunocompromised populations, whose germinal-center function, B-cell repertoire diversity, and overall immune responsiveness differ substantially from those of healthy younger recipients.

What the study establishes, with unusual molecular resolution, is a mechanistic bridge between a vaccine platform and the quality of the immunity it generates. Persistent germinal centers, diversified B-cell lineages, and a broader serum antibody repertoire form a coherent causal chain, and tools such as Ig-Seq now make each link observable in humans. As mRNA technology matures beyond its first applications, findings like these suggest that its most consequential contribution to vaccinology may lie not in speed of development but in the depth and breadth of the immune memory it leaves behind, offering a rational template for influenza vaccines designed to stay ahead of a virus that never stops changing.

Subject of Research: A clinical study comparing mRNA-1010 and Fluarix influenza vaccines in healthy adults, examining germinal-center persistence and antibody repertoire breadth

Article Title: Korea University study uncovers how mRNA vaccination may broaden flu antibody responses

Article References: Korea University study uncovers how mRNA vaccination may broaden flu antibody responses. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: mRNA vaccine, influenza, germinal center, antibody breadth, B cells, somatic hypermutation, Ig-Seq, neutralization, vaccinology, Nature Immunology, Korea University, immune repertoire